RPG Life Sciences Limited — Earnings Release 2026

Jan 27, 2026

==> picture [426 x 63] intentionally omitted <==

January 27, 2026

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051

Symbol: RPGLIFE

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers, Dalal Street, Mumbai 400 001

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of Press Release with respect to Unaudited Financial Results of the Company for the quarter ended December 31, 2025.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited

RAJESH Digitally signed by RAJESH RAMESH RAMESH SHIRAMBEKAR Date: 2026.01.27 19:22:09 SHIRAMBEKAR +05'30'

Rajesh Shirambekar Head – Legal & Company Secretary

Encl.: as above

==> picture [70 x 40] intentionally omitted <==

==> picture [160 x 62] intentionally omitted <==

Q3 FY26: Revenue up by 4.2% Y-o-Y and EBITDA margin at 24.0%

Mumbai, 27 January, 2026 : RPG Life Sciences Limited has announced its financial results for the third quarter ended 31 December, 2025.

==> picture [497 x 90] intentionally omitted <==

----- Start of picture text -----

Q-o-Q Revenue from operations
Q3 FY26 Highlights Rs. 180.0 crores vs. Rs. 181.7 crores
Y-o-Y Revenue from operations
Q3 FY26 Highlights Rs. 180.0 crores vs. Rs. 172.7 crores
9M FY26 Highlights Rs. 530.6 crores vs. Rs. 510.3 crores
----- End of picture text -----

In Q3 FY26 , RPG Life Sciences recorded a 4.2% Y-o-Y increase in revenue, along with a healthy EBITDA margin of 24.0%. For 9M FY26 , revenue grew 4.0% Y-o-Y, maintaining operational momentum.

Commenting on the results and the business outlook, Mr. Ashok Nair, Managing Director,

RPG Life Sciences Ltd., said, “Q3 reflects continued traction across our core businesses supported by disciplined execution and deliberate portfolio actions. Our Domestic Formulations business delivered growth ahead of the Indian Pharmaceutical Market, recording a growth of 11.8% in 9M FY26 compared to the IPM growth of 8.2%, driven by strong brand performance, improved field effectiveness, and sharper customer engagement. Our approach remains firmly rooted in quality and improving patient outcomes.”

“Looking ahead, we remain committed to building a future-ready pharmaceutical enterprise — one that is resilient, innovation-led, and people-first, creating sustainable value for patients, partners, and stakeholders, ” added Nair.

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company produces a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Group (www.rpggroup.com):

RPG Group, established in 1979, is one of India’s fastest-growing business groups with a turnover of US$ 5.2 billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact: Rashmi Menon – 88980 20577 | rashmi@rpg.in

==> picture [134 x 28] intentionally omitted <==